BidaskClub Lowers Voyager Therapeutics (NASDAQ:VYGR) to Sell

BidaskClub cut shares of Voyager Therapeutics (NASDAQ:VYGR) from a hold rating to a sell rating in a research report report published on Wednesday, BidAskClub reports.

A number of other equities analysts have also weighed in on the company. Wedbush lifted their price objective on Voyager Therapeutics from $27.00 to $36.00 and gave the company an outperform rating in a research note on Tuesday, June 18th. Morgan Stanley raised their target price on Voyager Therapeutics from $21.00 to $28.00 and gave the company an equal weight rating in a research report on Friday, July 12th. Nomura raised their target price on Voyager Therapeutics from $26.00 to $37.00 and gave the company a buy rating in a research report on Thursday, June 20th. Finally, HC Wainwright restated a buy rating and set a $22.00 target price on shares of Voyager Therapeutics in a research report on Monday, May 6th. One research analyst has rated the stock with a sell rating, two have given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. Voyager Therapeutics presently has a consensus rating of Buy and a consensus price target of $27.00.

Shares of NASDAQ VYGR traded down $0.15 during trading on Wednesday, reaching $20.53. 777,380 shares of the company traded hands, compared to its average volume of 355,879. The company has a fifty day moving average price of $24.74. The firm has a market cap of $753.22 million, a PE ratio of -7.47 and a beta of 2.55. Voyager Therapeutics has a 12-month low of $7.76 and a 12-month high of $28.79.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings data on Friday, August 9th. The company reported $0.29 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.88) by $1.17. The business had revenue of $46.09 million during the quarter, compared to analyst estimates of $5.25 million. Voyager Therapeutics had a negative return on equity of 129.67% and a negative net margin of 804.55%. On average, analysts forecast that Voyager Therapeutics will post -2.95 earnings per share for the current year.

Large investors have recently bought and sold shares of the company. Bank of New York Mellon Corp boosted its holdings in Voyager Therapeutics by 4.2% in the 4th quarter. Bank of New York Mellon Corp now owns 88,459 shares of the company’s stock worth $831,000 after buying an additional 3,543 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Voyager Therapeutics by 23.1% during the 4th quarter. Geode Capital Management LLC now owns 287,264 shares of the company’s stock worth $2,700,000 after purchasing an additional 53,888 shares during the last quarter. Bank of America Corp DE boosted its holdings in shares of Voyager Therapeutics by 211.0% during the 4th quarter. Bank of America Corp DE now owns 10,637 shares of the company’s stock worth $100,000 after purchasing an additional 7,217 shares during the last quarter. D. E. Shaw & Co. Inc. acquired a new position in shares of Voyager Therapeutics during the 4th quarter worth approximately $370,000. Finally, Squarepoint Ops LLC boosted its holdings in shares of Voyager Therapeutics by 131.7% during the 4th quarter. Squarepoint Ops LLC now owns 34,983 shares of the company’s stock worth $329,000 after purchasing an additional 19,883 shares during the last quarter. Hedge funds and other institutional investors own 73.92% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease.

Featured Story: Fundamental Analysis and Individual Investors

Analyst Recommendations for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.